Try our Advanced Search for more refined results
Health
-
April 09, 2026
Philly Injection Site Row Judge Rejects Nonprofit's 'Ploy'
A Pennsylvania federal judge on Thursday called the addition of overdose prevention nonprofit Safehouse's president as a counterclaim plaintiff in the government's suit to stop it from launching a safe-injection site in Philadelphia a "ploy" to add another to the ranks of those claiming the government infringed the group's religious freedom.
-
April 15, 2026
The 2026 Lawyer Satisfaction Survey: Where Do You Stand?
How is your work-life balance? Are you content with your compensation and opportunities for advancement at work? Take the 2026 Law360 Lawyer Satisfaction Survey and share your thoughts.
-
April 09, 2026
Ex-Pharmacy Director Denies Using Trade Secrets At New Job
A former director at a specialty infusion therapy pharmacy urged a New Jersey federal court to reject her former employer's bid to block her from working for a rival, arguing that her new job does not pose any threat of imminent harm to her former company.
-
April 09, 2026
Feds Cast Calif. Tribe's Opioid Clinic Fight As Money Grab
The federal government says it had justification for rejecting a California tribe's request for an agreement to fund an opioid treatment center, claiming that a challenge over the denial is more about trying to monetize on advantages available to Indigenous nations and less about helping patients.
-
April 09, 2026
Colo. Co. Failed To Prevent Patient Data Leak, Suit Says
A Colorado-based digital health company focused on reversing Type 2 diabetes is facing a proposed class action in federal court alleging it did not protect patients' personal and medical information from a cyberattack in late March that exposed their information to the dark web.
-
April 09, 2026
Elevance Nurses' Federal OT Suit Sent From NC To Va.
A class and collective action accusing insurer Elevance Health of misclassifying its nurses as overtime-exempt has been transferred from North Carolina to Virginia federal court, where the company faces related claims.
-
April 09, 2026
US Again Urges High Court To Back Drug Price Program
The administration of President Donald Trump again urged the Supreme Court not to hear a challenge to the Medicare drug price negotiation program, arguing against a constitutional challenge brought by Boehringer Ingelheim that drug companies aren't forced to accept lower prices because they can choose not to participate.
-
April 08, 2026
Ed. Dept. Says It's Not Required To Fund $1B In Youth Grants
The U.S. Department of Education denied accusations by 16 U.S. states that it is flouting a court order to restore nearly $1 billion in K–12 mental health grants, arguing in a Western District of Washington filing that the order required officials to re-review the grants, not actually provide full funding.
-
April 08, 2026
Va. Hospital Patient Seeks Final Nod For $3.1M Privacy Deal
An Inova Health Care Services patient is urging a Virginia federal judge to grant final approval to a $3.1 million deal to resolve claims the healthcare system unlawfully shared private health information with Meta and Google through online tracking tools, arguing the resolution has received "overwhelming support" from the settlement class.
-
April 08, 2026
Fla. Insurer, Ex-Parent To Pay $135M Over ACA Fraud Scheme
A Florida insurer and its former parent, which is a Delaware-based national partnership of insurance brokers, have agreed to pay $135 million collectively to resolve allegations of a scheme to enroll ineligible consumers into subsidized Affordable Care Act plans and of defrauding the federal government of more than $140 million.
-
April 08, 2026
Biz Judge Keeps Doc Class Action Against Luxottica, For Now
A Texas Business Court judge Wednesday kept alive, on procedural grounds, a proposed class action made up of Texas optometrists who say that their office space deals with eye care giant Luxottica of America Inc. didn't follow Texas law.
-
April 08, 2026
AbbVie Says 340B Program Defines 'Patient' Too Broadly
Federally funded healthcare providers in the 340B Drug Pricing Program are using an "overly broad" interpretation of the word "patient" based on government guidelines, and it's leading to them abusing 340B discounts, AbbVie claimed in a lawsuit filed against two federal health agencies Wednesday.
-
April 08, 2026
No Surprises Act Bars Provider's Award Enforcement Bid
A Pennsylvania federal court declined to force an insurer to pay over $300,000 in alleged outstanding payments from an out-of-network billing dispute with a provider, finding it lacked authority to do so under the No Surprises Act.
-
April 08, 2026
States Seek Time For Talks To Settle Drug Price-Fixing Suit
The states suing generic-drug manufacturers in one of three sprawling antitrust cases want a Connecticut federal judge to pause all deadlines for three months so they can focus on settling with the remaining defendants, according to a joint filing.
-
April 08, 2026
3M Settles Ex-Worker's COVID Vax Firing Suit
A former 3M Co. employee who claimed the company's COVID-19 vaccination mandate policy was "unnecessary" and "draconian" has settled his more than 3-year-old suit over his firing, according to a court filing.
-
April 08, 2026
Lost Data Should Get Co. Punished In EEOC Suit, Judge Says
A Georgia federal judge recommended sanctions against a cosmetic surgery provider for neglecting to keep sales data and messages, saying the information could've been relevant in a disability bias suit the U.S. Equal Employment Opportunity Commission brought on a former worker's behalf.
-
April 08, 2026
Abbott Urges Ill. Jury To Reject Claims Formula Led To NEC
Counsel for Abbott Laboratories told an Illinois jury Wednesday that four infants, whose mothers allege the company's preterm baby formula caused their serious intestinal illness, would have developed the disease "even without a drop of formula" given other risk factors and that the absence of other feeding options at the time of the babies' births dooms their parents' claims.
-
April 08, 2026
ERISA Recap: 6 Noteworthy Decisions From March
JPMorgan Chase & Co. narrowed but couldn't escape a suit from workers who said their health plan paid too much for prescription drugs, Genworth Financial Inc. unwound a class at the Fourth Circuit, and the Sixth Circuit breathed new life into proposed class actions against FedEx and Kellogg. Here, Law360 looks at these and three other notable decisions from March in ERISA cases.
-
April 08, 2026
Pa. Panel Splits Bellwether Pediatrician Sex Abuse Trial
A Pennsylvania appeals court has reversed an order consolidating four civil cases against a hospital and pediatrics association related to sexual abuse allegations against a now-incarcerated doctor, saying putting the four cases together in one trial would prejudice the defendants and likely confuse the jury.
-
April 08, 2026
Biopharma-Focused Jeito Wraps 2nd Fund With $1.2B In Tow
Biopharmaceutical-focused private equity shop Jeito Capital, advised by Goodwin Procter LLP, on Wednesday announced that it closed its second fund above target after raising more than €1 billion ($1.2 billion) from investors.
-
April 08, 2026
$37M Award For Whistleblowers Nixed In Medicaid Fraud Row
A Texas state appeals court did away with an order awarding three whistleblowers a $37 million share of the state's settlement resolving Medicaid fraud allegations against Xerox, finding their respective cases over the alleged scheme were based on publicly available information.
-
April 08, 2026
Whistleblower, Healthcare Operator End Retaliation Suit
A nursing home administrator who participated in a U.S. Department of Housing and Urban Development whistleblower investigation into alleged false payment claims and a healthcare facility operator agreed to end a lawsuit over his firing, according to a stipulation filed in Colorado federal court Wednesday.
-
April 08, 2026
FedEx Says NY Attys And Medical Providers Staged Crashes
FedEx accused a network of lawyers, medical providers and clinics of orchestrating an insurance scam in which they staged motor vehicle accidents in order to defraud the delivery giant through sham lawsuits and inflated medical bills, according to a suit filed in New York federal court.
-
April 08, 2026
Faegre Drinker Hires 2 Venable FDA Partners In DC
Faegre Drinker Biddle & Reath LLP has hired two attorneys from Venable LLP who joined that firm in 2023 and focus their practices on helping clients understand U.S. Food and Drug Administration regulatory frameworks, the firm announced Wednesday.
-
April 08, 2026
HIV, AIDS Patients End Disability Bias Suit With CVS
CVS Pharmacy Inc. and a group of HIV and AIDS patients have agreed to wrap up a suit claiming the company made it harder for them to get their medication in violation of disability discrimination law, according to a California federal court filing.
Expert Analysis
-
Trans Care Enforcement Landscape Is Evolving Quickly
The recent coordinated federal effort to reshape pediatric gender-affirming care through enforcement and funding pressure has created a rapidly evolving regulatory environment marked by shifting risk assessments and potential downstream market effects for healthcare institutions and life sciences companies, say attorneys at Arnall Golden.
-
Series
Playing Piano Makes Me A Better Lawyer
Playing piano and practicing law share many parallels relating to managing complexity: Just as hearing an entire musical passage in my head allows me to reliably deliver the message, thinking about the audience's impression helps me create a legal narrative that keeps the reader engaged, says Michael Shepherd at Fish & Richardson.
-
11th Circ. May Bring Tectonic Shift To FCA Qui Tam Actions
The Eleventh Circuit's upcoming decision in Zafirov v. Florida Medical Associates, assessing whether the False Claims Act permits ordinary citizens to stand as officers of the federal government, could significantly limit private relators' ability to bring FCA actions, say attorneys at Saul Ewing.
-
AI-Generated Doc Ruling Guides Attys On Privilege Risks
A New York federal court's ruling, in U.S. v. Heppner, that documents created by a defendant using an artificial intelligence tool were not privileged, can serve as a guide to attorneys for retaining attorney-client or work-product privilege over client documents created with AI, say attorneys at Sher Tremonte.
-
To Survive FCA Actions, Small Cos. Must Take Offensive Steps
A fumbled response to False Claims Act allegations can doom lower-middle-market businesses, and with FCA enforcement hitting record levels for two years, smaller companies must have offensive strategies ready that focus their limited resources on defeating civil qui tam and federal criminal actions, says Derrelle Janey at Olshan Frome.
-
The Law Firm Merger Diaries: Leadership Strategy After Day 1
For law firm leaders, ensuring a newly combined law firm lives up to its promise, both in its first days of operation and well after, includes tough decisions, clear and specific communication, and cheerleading, says Peter Michaud at Ballard Spahr.
-
How US Liability Law Is Becoming The Primary Regulator Of AI
Comprehensive federal AI regulation remains fragmented and uncertain — but U.S. courts, applying long-standing doctrines of liability and responsibility, are actively shaping how AI systems are designed, deployed and governed, and companies are aligning their AI practices because courts may hold them accountable if they do not, says Alexander Lima at Wesco International.
-
Record FCA Recoveries Signal Intensified Healthcare Focus
In its recently released False Claims Act statistics, the U.S. government's emphasis on record healthcare recoveries and government-initiated healthcare matters last year indicates robust enforcement ahead, though the administration's focus on current policy objectives also extends beyond the healthcare sector, say attorneys at Epstein Becker.
-
Fed. Circ. In Jan.: On The Validity Of Expert Testimony
The Federal Circuit's recent decision in Barry v. DePuy, addressing whether expert testimony is admissible even if it does not strictly adhere to the court's claim construction, suggests that exclusion via a Daubert motion is appropriate only when the line to improper testimony is clearly crossed, say attorneys at Knobbe Martens.
-
Methods For Challenging State Civil Investigative Demands
Ongoing challenges to enforcement actions underscore the uphill battle businesses face in arguing that a state investigation is prohibited by federal law, but when properly deployed, these arguments present a viable strategy to resist civil investigative demands issued by state attorneys general, say attorneys at Troutman Pepper.
-
Calif.'s Civility Push Shows Why Professionalism Is Vital
The California Bar’s campaign against discourteous behavior by attorneys, including a newly required annual civility oath, reflects a growing concern among states that professionalism in law needs shoring up — and recognizes that maintaining composure even when stressed is key to both succeeding professionally and maintaining faith in the legal system, says Lucy Wang at Hinshaw.
-
A Potential Shift In FDA's Approach To Drug Trial Design
Recent guidance released by the U.S. Food and Drug Administration clarifying how Bayesian approaches — which combine prior knowledge with new data — may be used in clinical trials reflects the agency's continued interest in innovative trial designs that may accelerate drug approvals, say attorneys at Alston & Bird.
-
Opinion
SNAP Rule Confusion Risks A Compliance Crisis
Recent Supplemental Nutrition Assistance Program food restriction waivers pose a compliance crisis for legal practitioners advising food retailers, amid higher costs and lack of a coherent national standard, says Tyson-Lord Gray at Yeshiva University’s Benjamin N. Cardozo School of Law.
-
Series
Trivia Competition Makes Me A Better Lawyer
Playing trivia taught me to quickly absorb information and recognize when I've learned what I'm expected to know, training me in the crucial skills needed to be a good attorney, and reminding me to be gracious in defeat, says Jonah Knobler at Patterson Belknap.
-
What FDA Guidance Means For Future Of Health Software
Two significant final guidance documents released by the U.S. Food and Drug Administration last month reflect a targeted effort to ease innovation friction around specific areas, including singular clinical decision support recommendations and sensor-based wearables, while maintaining established regulatory boundaries, say attorneys at Covington.